Crerar M M, Leather R, David E, Pearson M L
Mol Cell Biol. 1983 May;3(5):946-55. doi: 10.1128/mcb.3.5.946-955.1983.
To assess the functional role of RNA polymerase II in the regulation of transcription during muscle differentiation, we isolated and characterized a large number of independent alpha-amanitin-resistant (AmaR) mutants of L6 rat myoblasts that express both wild-type and altered RNA polymerase II activities. We also examined their myogenic (Myo) phenotype by determining their ability to develop into mature myotubes, to express elevated levels of muscle creatine kinase, and to synthesize muscle-characteristic proteins as detected by two-dimensional polyacrylamide gel electrophoresis. We found a two- to threefold increase in the frequency of clones with a myogenic-defective phenotype in the AmaR (RNA polymerase II) mutants as compared to control ethyl methane sulfonate-induced, 6-thioguanine-resistant (hypoxanthine, guanine phosphoribosyl transferase) mutants or to unselected survivors also exposed to ethyl methane sulfonate. Subsequent analysis showed that about half of these myogenic-defective AmaR mutants had a conditional Myo(ama) phenotype; when cultured in the presence of amanitin, they exhibited a Myo- phenotype; in its absence they exhibited a Myo+ phenotype. This conditional Myo(ama) phenotype is presumably caused by the inactivation by amanitin of the wild-type amanitin-sensitive RNA polymerase II activity and the subsequent rise in the level of mutant amanitin-resistant RNA polymerase II activity. In these Myo(ama) mutants, the wild-type RNA polymerase II is normally dominant with respect to the Myo+ phenotype, whereas the mutant RNA polymerase II is recessive and results in a Myo- phenotype only when the wild-type enzyme is inactivated. These findings suggest that certain mutations in the amaR structural gene for the amanitin-binding subunit of RNA polymerase II can selectively impair the transcription of genes specific for myogenic differentiation but not those specific for myoblast proliferation.
为了评估RNA聚合酶II在肌肉分化过程中转录调控中的功能作用,我们分离并鉴定了大量独立的L6大鼠成肌细胞α-鹅膏蕈碱抗性(AmaR)突变体,这些突变体同时表达野生型和改变的RNA聚合酶II活性。我们还通过测定它们发育成成熟肌管的能力、表达升高水平的肌肉肌酸激酶的能力以及通过二维聚丙烯酰胺凝胶电泳检测合成肌肉特征性蛋白质的能力,来检测它们的成肌(Myo)表型。我们发现,与对照的乙基甲磺酸诱导的6-硫鸟嘌呤抗性(次黄嘌呤-鸟嘌呤磷酸核糖转移酶)突变体或同样暴露于乙基甲磺酸的未选择存活细胞相比,AmaR(RNA聚合酶II)突变体中具有成肌缺陷表型的克隆频率增加了两到三倍。随后的分析表明,这些成肌缺陷的AmaR突变体中约一半具有条件性Myo(ama)表型;当在鹅膏蕈碱存在下培养时,它们表现出Myo-表型;在其不存在时,它们表现出Myo+表型。这种条件性Myo(ama)表型可能是由于鹅膏蕈碱使野生型鹅膏蕈碱敏感的RNA聚合酶II活性失活,以及随后突变的鹅膏蕈碱抗性RNA聚合酶II活性水平升高所致。在这些Myo(ama)突变体中,野生型RNA聚合酶II在Myo+表型方面通常占主导地位,而突变型RNA聚合酶II是隐性的,只有当野生型酶失活时才会导致Myo-表型。这些发现表明,RNA聚合酶II的鹅膏蕈碱结合亚基的amaR结构基因中的某些突变可以选择性地损害成肌分化特异性基因的转录,但不会损害成肌细胞增殖特异性基因的转录。